Search Results 901-910 of 21762 for Secondary

  1. Breast cancer - Doctors and departments - Mayo Clinic

    ... Secondary hyperparathyroidism, Parathyroid disease, Tertiary hyperparathyroidism, Multinodular goiter, Insulinoma, Aldosteronoma, BRCA gene mutation, MEN 2B.

  2. Breast cancer - Doctors and departments - Mayo Clinic

    ... Secondary hyperparathyroidism, Parathyroid disease, Tertiary hyperparathyroidism, Multinodular goiter, Insulinoma, Aldosteronoma, BRCA gene mutation, MEN 2B.

  3. Breast cancer - Doctors and departments - Mayo Clinic

    ... Secondary hyperparathyroidism, Parathyroid disease, Tertiary hyperparathyroidism, Multinodular goiter, Insulinoma, Aldosteronoma, BRCA gene mutation, MEN 2B.

  4. Breast cancer - Doctors and departments - Mayo Clinic

    ... Secondary hyperparathyroidism, Parathyroid disease, Tertiary hyperparathyroidism, Multinodular goiter, Insulinoma, Aldosteronoma, BRCA gene mutation, MEN 2B.

  5. Breast cancer - Doctors and departments - Mayo Clinic

    ... Secondary hyperparathyroidism, Parathyroid disease, Tertiary hyperparathyroidism, Multinodular goiter, Insulinoma, Aldosteronoma, BRCA gene mutation, MEN 2B.

  6. Study of ASTX727 vs IV Decitabine in MDS and CMML - Mayo Clinic

    Men or women ≥18 years who are candidates to receive IV decitabine, ie, subjects with MDS previously treated or untreated with de novo or secondary MDS ...

  7. Surgery - Doctors - Mayo Clinic

    ... Secondary hyperparathyroidism, Pediatric endocrine disorder, Pediatric adrenal disorder, Parathyroid disease, Multinodular goiter, Insulinoma, MEN 2B ...

  8. Clinical trials - Oncology (Medical)

    This may lead to an increased risk of serious infections requiring hospitalization and an increased risk of secondary non-blood-based (hematologic) cancers.

  9. Neurosurgery - Clinical trials

    ... secondary myelofibrosis (MF) displaying mutated calreticulin (muCALR); (3) Cohort 3 focuses on glioblastoma multiforme (GBM) which often displays the ...

  10. Clinical trials - Oncology (Medical)

    This may lead to an increased risk of serious infections requiring hospitalization and an increased risk of secondary non-blood-based (hematologic) cancers.